Who bears the risks of stock tokenization? My assessment is that, in the short term, they are borne mainly by listed companies and secondary-market investors—not by “the entire market,” as the advertisements imply. The reason is that tokenized trading venues are allowed to delay trade disclosures and are not required to interoperate with the market for underlying shares. As a result, price discovery and liquidity fragmentation first affect individual stocks.
First, the facts. According to a translation by PANews, on October 24–25, 2026, The Wall Street Journal published a full-page paid advertisement funded by the Common Sense Leadership Fund. Addressed to the CEOs of listed companies, it outlined eight risks of stock tokenization, including price divergence, opaque share ownership, impaired financing capacity, market manipulation, and legal liability, and called on companies to exercise their right to object. The organization is a conservative U.S. nonprofit, and these eight risks are its claims, not proven conclusions.
The objection-right mechanism deserves closer attention. According to Nasdaq’s FAQ, on September 17 the SEC issued a temporary, conditional exemption allowing qualifying tokenized securities trading venues to trade tokenized stocks. A venue must notify the company in writing in advance. The company then has 30 calendar days from receipt of the notice to object. An objection applies only to the venue that issued the notice, so companies must address each platform separately. The exemption requires token holders to have rights—including voting, dividends, and liquidation rights—comparable to those of holders of the same class of traditional shares. Synthetic products are not covered.
My observation is that this arrangement shifts the burden of assessment onto companies: notices are distributed across venues, and each deadline starts separately. If a company does not respond to each one, the token can be listed on that platform. Meanwhile, TSVs are not required to use real-time consolidated quotes; trade disclosures can be delayed by up to 10 minutes, and cross-venue interoperability is not mandatory, potentially fragmenting liquidity. Based on this, I infer that small-cap stocks’ pricing efficiency and the transparency of their shareholder registers would be affected first—not the financing capacity of blue-chip companies, for which evidence is still lacking.
What would invalidate this assessment: if the price gap between tokens and underlying shares narrows over the long term, trading volume does not shift significantly away from the underlying shares, and companies’ objection lists stabilize, then these concerns may have been overstated. The indicators to track are the price gap, the proportion of trading volume that migrates, and changes in the objection lists.
#监管 #Crypto Market
Sources:
PANews (originally published 10-27 at 16:44 Beijing time)
https://www.panewslab.com/zh/articles/01a17c49-5318-7610-bace-3cbbfd70a4bd
First, the facts. According to a translation by PANews, on October 24–25, 2026, The Wall Street Journal published a full-page paid advertisement funded by the Common Sense Leadership Fund. Addressed to the CEOs of listed companies, it outlined eight risks of stock tokenization, including price divergence, opaque share ownership, impaired financing capacity, market manipulation, and legal liability, and called on companies to exercise their right to object. The organization is a conservative U.S. nonprofit, and these eight risks are its claims, not proven conclusions.
The objection-right mechanism deserves closer attention. According to Nasdaq’s FAQ, on September 17 the SEC issued a temporary, conditional exemption allowing qualifying tokenized securities trading venues to trade tokenized stocks. A venue must notify the company in writing in advance. The company then has 30 calendar days from receipt of the notice to object. An objection applies only to the venue that issued the notice, so companies must address each platform separately. The exemption requires token holders to have rights—including voting, dividends, and liquidation rights—comparable to those of holders of the same class of traditional shares. Synthetic products are not covered.
My observation is that this arrangement shifts the burden of assessment onto companies: notices are distributed across venues, and each deadline starts separately. If a company does not respond to each one, the token can be listed on that platform. Meanwhile, TSVs are not required to use real-time consolidated quotes; trade disclosures can be delayed by up to 10 minutes, and cross-venue interoperability is not mandatory, potentially fragmenting liquidity. Based on this, I infer that small-cap stocks’ pricing efficiency and the transparency of their shareholder registers would be affected first—not the financing capacity of blue-chip companies, for which evidence is still lacking.
What would invalidate this assessment: if the price gap between tokens and underlying shares narrows over the long term, trading volume does not shift significantly away from the underlying shares, and companies’ objection lists stabilize, then these concerns may have been overstated. The indicators to track are the price gap, the proportion of trading volume that migrates, and changes in the objection lists.
#监管 #Crypto Market
Sources:
PANews (originally published 10-27 at 16:44 Beijing time)
https://www.panewslab.com/zh/articles/01a17c49-5318-7610-bace-3cbbfd70a4bd
